Overview
etherna is a Belgian biotech company specializing in nucleic acid-based medicines, particularly mRNA therapeutics and customizable Lipid Nanoparticles (cLNPs) for targeted delivery. They provide development and manufacturing support to partners creating therapeutics and vaccines, with expertise in RNA chemistry and process technologies. Their platforms enable scalable, high-quality production, including lyophilized mRNA/LNP formulations, and have shown preclinical success in cancer immunotherapy.
Frequently asked questions
- What are etherna's core technology platforms?
- etherna offers advanced mRNA platforms for optimization and selection, along with customizable Lipid Nanoparticles (cLNPs) for extrahepatic delivery, supported by RNA chemistry and process technologies.
- What therapeutic areas does etherna target?
- etherna focuses on nucleic acid-based medicines for cancer immunotherapy, infectious diseases, and vaccines, with preclinical data showing tumor regression in models like triple-negative breast cancer.
- Where is etherna headquartered and what is their regulatory experience?
- Headquartered in Niel, Belgium, etherna supports partners in development and manufacturing of nucleic acid therapeutics; they have advanced platforms like LAD116 to clinical stages.